JP2022517399A - Ｃｄ３８に特異的な二環式ペプチドリガンド - Google Patents

Ｃｄ３８に特異的な二環式ペプチドリガンド Download PDF

Info

Publication number
JP2022517399A
JP2022517399A JP2021541187A JP2021541187A JP2022517399A JP 2022517399 A JP2022517399 A JP 2022517399A JP 2021541187 A JP2021541187 A JP 2021541187A JP 2021541187 A JP2021541187 A JP 2021541187A JP 2022517399 A JP2022517399 A JP 2022517399A
Authority
JP
Japan
Prior art keywords
seq
referred
sar
peptide ligand
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021541187A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020148530A5 (enExample
Inventor
バルダッサーレ レオナルド
ラニ ラシッド
パヴァン シルヴィア
ステイス キャサリン
トイフェル ダニエル
Original Assignee
バイスクルアールディー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイスクルアールディー・リミテッド filed Critical バイスクルアールディー・リミテッド
Publication of JP2022517399A publication Critical patent/JP2022517399A/ja
Publication of JPWO2020148530A5 publication Critical patent/JPWO2020148530A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021541187A 2019-01-15 2020-01-15 Ｃｄ３８に特異的な二環式ペプチドリガンド Pending JP2022517399A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1900530.5A GB201900530D0 (en) 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for CD38
GB1900530.5 2019-01-15
PCT/GB2020/050074 WO2020148530A1 (en) 2019-01-15 2020-01-15 Bicyclic peptide ligands specific for cd38

Publications (2)

Publication Number Publication Date
JP2022517399A true JP2022517399A (ja) 2022-03-08
JPWO2020148530A5 JPWO2020148530A5 (enExample) 2023-01-25

Family

ID=65528178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021541187A Pending JP2022517399A (ja) 2019-01-15 2020-01-15 Ｃｄ３８に特異的な二環式ペプチドリガンド

Country Status (6)

Country Link
US (1) US20220133733A1 (enExample)
EP (1) EP3911366A1 (enExample)
JP (1) JP2022517399A (enExample)
CN (1) CN113597317A (enExample)
GB (1) GB201900530D0 (enExample)
WO (1) WO2020148530A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3215518T1 (sl) 2014-10-29 2021-08-31 Bicyclerd Limited Biciklični peptidni ligandi, značilni za MT1-MMP
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
WO2019162682A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
WO2020128526A1 (en) 2018-12-21 2020-06-25 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
GB202016331D0 (en) * 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514104A (ja) * 2002-12-12 2006-04-27 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． グリコーゲンシンターゼキナーゼ−３阻害剤
JP2017519041A (ja) * 2014-05-21 2017-07-13 シクロポーターズ，インコーポレイテッド 細胞膜透過性ペプチド、並びにこの作製方法及び使用方法
US20180118786A1 (en) * 2015-04-28 2018-05-03 Ecole Polytechnique Federale De Lausanne (Epfl) NOVEL lNHIBITORS OF THE ENZYME ACTIVATED FACTOR XII (FXIIA)
WO2019002842A1 (en) * 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
ES2541436T3 (es) 2004-02-06 2015-07-20 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
PL1844337T3 (pl) 2005-01-24 2013-12-31 Pepscan Systems Bv Związki wiążące, związki immunogenne i peptydomimetyki
MX2007011064A (es) * 2005-03-23 2008-02-19 Genmab As Anticuerpos contra cd38 para tratamiento de mieloma multiple.
ES2509959T5 (en) 2008-02-05 2024-12-19 Bicyclerd Ltd Methods and compositions
SI3215518T1 (sl) 2014-10-29 2021-08-31 Bicyclerd Limited Biciklični peptidni ligandi, značilni za MT1-MMP
GB201810320D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514104A (ja) * 2002-12-12 2006-04-27 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． グリコーゲンシンターゼキナーゼ−３阻害剤
JP2017519041A (ja) * 2014-05-21 2017-07-13 シクロポーターズ，インコーポレイテッド 細胞膜透過性ペプチド、並びにこの作製方法及び使用方法
US20180118786A1 (en) * 2015-04-28 2018-05-03 Ecole Polytechnique Federale De Lausanne (Epfl) NOVEL lNHIBITORS OF THE ENZYME ACTIVATED FACTOR XII (FXIIA)
WO2019002842A1 (en) * 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIUHONG CHEN, ET AL.: "The Bicycle platform: an efficient technology to generate high affinity, high selectivity molecules", BICYCLE THERAPEUTICS PUBLICATIONS [ONLINE], JPN6023022584, 2017, ISSN: 0005360628 *

Also Published As

Publication number Publication date
US20220133733A1 (en) 2022-05-05
EP3911366A1 (en) 2021-11-24
CN113597317A (zh) 2021-11-02
WO2020148530A1 (en) 2020-07-23
GB201900530D0 (en) 2019-03-06

Similar Documents

Publication Publication Date Title
JP2022517399A (ja) Ｃｄ３８に特異的な二環式ペプチドリガンド
TWI862640B (zh) 異質雙環肽複合物
JP7503689B2 (ja) ＥｐｈＡ２に特異的な二環ペプチドリガンド
JP2024023291A (ja) 多量体二環式ペプチドリガンド
JP2022514618A (ja) Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
JP2022517040A (ja) Ｃｄ３８に特異的な二環式ペプチドリガンド
JP2022514255A (ja) Ｐｓｍａに特異的な二環式ペプチドリガンド
JP2022517442A (ja) Ｃａｉｘに特異的な二環式ペプチドリガンド
JP2022514687A (ja) Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
JP2022552839A (ja) 二環式ペプチドリガンド薬物コンジュゲート
JP2022518695A (ja) Ｃａｉｘに特異的な二環式ペプチドリガンド
JP2022532134A (ja) Ｏｘ４０に特異的な二環式ペプチドリガンド
JP2020529427A (ja) Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
JP2022513806A (ja) Ｍｔ１－ｍｍｐに特異的な二環式ペプチドリガンド
JP2022518210A (ja) インテグリンαｖβ３に特異的な二環式ペプチドリガンド
JP2022513223A (ja) Ｍｔ１－ｍｍｐに特異的な二環式ペプチドリガンド
JP2022512478A (ja) Ｍｔ１－ｍｍｐに特異的な二環式ペプチドリガンド
JP2021528432A (ja) Ｃｄ３８に結合するためのペプチドリガンド
JP2022515720A (ja) Ｉｌ－１７に特異的な二環式ペプチドリガンド
CN117203219A (zh) 特异性针对p-选择素的双环肽配体
JP2022515721A (ja) ＦＡＰαに特異的な二環式ペプチドリガンド
WO2022079445A1 (en) Bicyclic peptide ligand drug conjugates
JP2024536391A (ja) 二環式ペプチドリガンド薬物コンジュゲート

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240702